Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CRBP
STRONG SELLCorbus Pharmaceuticals Holdings, Inc. · Healthcare · United States · $170M · Avg Vol: $4M/d
COMPANY DESCRIPTION
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company developing novel small molecule therapies for inflammatory, fibrotic, and cancer indications. The company focuses on targeting specific biological pathways to address diseases with high unmet medical needs. Its pipeline, including agents for oncology and rare diseases, positions it in the competitive biotechnology landscape.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 1.1M | 2.4M | — |
| EPS | -2.29 | -2.46 | -3.68 | -5.90 | — | -5.63 | -4.57 | -5.08 | — |
| Shares | 18.5M | 18.5M | 12.2M | 17.6M | -4.9% | 18.5M | — | — | — |
| Debt | 25.1M | 20.9M | 3.2M | 1.6M | -59.8% | 1.2M | — | — | — |
| Equity | 33.0M | -6.9M | 142.4M | 147.5M | 64.7% | — | — | — | — |
| Op CF | -37.5M | -36.1M | -41.8M | -64.5M | — | -73.6M | — | — | — |
| Inv CF | 30.1M | 35.6M | -121.3M | -1.6M | — | — | — | — | — |
| Fin CF | -0.5M | -2.8M | 166.6M | 77.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRBP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CRBP | Corbus Pharmaceuticals Holdings, Inc.(you) | $170M | 15 | STRONG SELL |
| TNYA | Tenaya Therapeutics, Inc. | $168M | 15 | STRONG SELL |
| PYXS | Pyxis Oncology, Inc. | $165M | 14 | STRONG SELL |
| ARCT | Arcturus Therapeutics Holdings Inc. | $157M | 15 | STRONG SELL |
| VYGR | Voyager Therapeutics, Inc. | $187M | 15 | STRONG SELL |
| ABOS | Acumen Pharmaceuticals, Inc. | $154M | 15 | STRONG SELL |
| NERV | Minerva Neurosciences, Inc. | $188M | 16 | STRONG SELL |
| CNTN | Canton Strategic Holdings, Inc. | $150M | 15 | STRONG SELL |
| RNA | Atrium Therapeutics, Inc. | $197M | 16 | STRONG SELL |
| UNCY | Unicycive Therapeutics, Inc. | $148M | 14 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%